What role does albumin play in paclitaxel's cellular uptake?

Short answer: albumin is the delivery vehicle. In albumin-bound paclitaxel formulations (e.g., nab-paclitaxel/Abraxane), albumin facilitates transport from blood into tumors and helps concentrate the drug there.

Key points:
- Solubility/ formulation: Paclitaxel is bound to albumin to make a soluble, Cremophor-free nanoparticle, improving tolerability and enabling systemic delivery.
- Endothelial transport: Albumin can bind to the gp60 (albondin) receptor on vascular endothelial cells and trigger caveolae-mediated transcytosis. This helps move the albumin-bound paclitaxel across the tumor blood vessel wall into the tumor interstitial space.
- Tumor retention/concentration: The tumor stroma often expresses SPARC (osteonectin), which can bind albumin. This binding helps trap albumin-bound paclitaxel in the tumor, increasing local drug exposure.
- Drug release and uptake: Once in the tumor interstitium, paclitaxel is released from the albumin and taken up by tumor cells, where it exerts its microtubule-inhibiting, anti-cancer effects.
- Clinical relevance: This mechanism helps explain the efficacy and some tolerability advantages of nab-paclitaxel over solvent-based formulations in several cancers. However, the predictive value of SPARC and the exact uptake pathways can vary by tumor type and are still an area of ongoing research.

If you’d like, I can summarize specific studies linking SPARC or gp60 to nab-paclitaxel uptake in particular cancers.